Improved haemagglutinin antigen content in H5N1 candidate vaccine viruses with chimeric haemagglutinin molecules

Vaccine

Volumn 28, Issue 50, 2010, Pages 8008-8014

  Harvey, Ruth ^a   Nicolson, Carolyn ^a   Johnson, Rachel E ^a   Guilfoyle, Kate A ^a   Major, Diane L ^a   Robertson, James S ^a   Engelhardt, Othmar G ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Candidate vaccine virus; Haemagglutinin; Influenza; Vaccine

Indexed keywords

CHIMERIC PROTEIN; HEMAGGLUTININ; NIBRG 14 VACCINE; SIALIDASE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ARTICLE; CONTROLLED STUDY; DEGLYCOSYLATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENE SEQUENCE; IMMUNOGENICITY; INFLUENZA VIRUS A H5N1; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CHICKENS; CHIMERA; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; OVUM; PLASMIDS; TURKEYS;

EID: 78650248582     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.006     Document Type: Article

References (23)

1. World Health Organisation (WHO) Antigenic and genetic characteristics of influenza A(H5N1) viruses and candidate vaccine viruses developed for potential use in human vaccines. September 2009 (September), Global Alert and Response (GAR), WHO, Website http://www.who.int/csr/disease/influenza/200909_H5VaccineVirusUpdate.pdf.
2. WHO. Website http://www.who.int/csr/disease/avian_influenza/en/index.html.
3. Subbarao K., Chen H., Swayne D., Mingay L., Fodor E., Brownlee G., et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 2003, 305:192-200.
4. Nicolson C., Major D., Wood J.M., Robertson J.S. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system. Vaccine 2005, 23:2943-2952.
5. Bresson J., Perronne C., Launay O., Gerdil C., Saville M., Wood J.M., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. The Lancet 2006, 367:1657-1664.
6. Leroux-Roels I., Borkowski A., Vanwolleghem T., Dramé M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. The Lancet 2007, 370:580-589.
7. Levie K., Leroux-Roels I., Hoppenbrouwers K., Kervyn A., Vandermeulen C., Forgus S., et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. Journal of Infectious Diseases 2008, 198:642-649.
8. Nolan T.M., Richmond P.C., Skeljo M.V., Pearce G., Hartel G., Formica N.T., et al. Phases I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine 2008, 26:4160-4167.
9. Nolan T., Richmond P.C., Formica N.T., Höschler K., Skeljo M.V., Stoney T., et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 2008, 26:6383-6391.
10. Harvey R., Wheeler J.X., Wallis C.L., Robertson J.S., Engelhardt O.E. Quantitation of haemagglutinin in H5N1 influenza viruses reveals low haemagglutinin content of vaccine virus NIBRG-14 (H5N1). Vaccine 2008, 26:6550-6554.
11. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. The American Journal of Hygiene 1938, 27:493-497.
12. Wood J.M., Schild G.C., Newman R.M., Seagroatt V. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for the potency determinations of inactivated whole virus and subunit vaccines. Journal of Biological Standardisation 1977, 5:237-247.
13. Kendal AP, Pereira MS, Skehel JJ. Concepts and procedures for laboratory based influenza surveillance. Atlanta U.S. Department of Health and Human Services, Centers for Disease Control 1982.
14. Hsu J.C. Multiple comparisons, theory and methods 1996, Chapman and Hall.
15. Horimoto T., Murakami S., Muramoto Y., Yamada S., Fujii K., Kiso M., et al. Enhanced growth of seed viruses for H5N1 influenza vaccines. Virology 2007, 366(1):23-27.
16. Adamo J.E., Liu T., Schmeisser F., Ye Z. Optimizing viral protein yield of influenza strain A/Vietnam/1203/2004 by modification of the neuraminidase gene. Journal of Virology 2009, 83(9):4023-4029.
17. Scheiffele P., Roth M.G., Simons K. Interaction of influenza virus haemagglutinin with sphingolipid-cholesterol membrane domains via its transmembrane domain. The EMBO Journal 1997, 16(18):5501-5508.
18. Takeda M., Leser G.P., Russell C.J., Lamb R.A. Influenza virus hemagglutinin concentrates in lipid raft microdomains for efficient viral fusion. PNAS 2003, 100(25):14610-14617.
19. Lin S., Naim H.Y., Rodriguez A.C., Roth M.G. Mutations in the middle of the transmembrane domain reverse the polarity of transport of the influenza virus hemagglutinin in MDCK epithelial cells. Journal of Cell Biology 1998, 142(1):51-57.
20. Watanabe T., Watanabe S., Noda T., Fujii Y., Kawaoka Y. Exploitation of nucleic acid packaging signals to generate a novel influenza virus-based vector stably expressing two foreign genes. Journal of Virology 2003, 77(19):10575-10583.
21. Marsh A., Hatami R., Palese P. Specific residues of the influenza A virus hemagglutinin viral RNA are important for efficient packaging into budding virions. Journal of Virology 2007, 81(18):9727-9736.
22. Ljungberg K., Wahren B., Almqvist J., Hinkula J., Linde A., Winberg G. Effective construction of DNA vaccines against variable influenza genes by homologous recombination. Virology 2000, 268:244-250.
23. Ljungberg K., Kolmskog C., Wahren B., Van Amerongen G., Baars M., Osterhaus A., et al. DNA vaccination of ferrets with chimeric influenza A virus hemagglutinin (H3) genes. Vaccine 2002, 20:2045-2052.